Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics develops rapid, near-patient diagnostic testing for critical care settings through its Symphony™ platform. The company’s lead product candidate, the Symphony™ IL-6 Test, is designed to measure interleukin-6 for sepsis triage, patient monitoring, and risk assessment, with sample-to-result testing described at approximately 20 minutes.
Bluejay news commonly covers SYMON clinical studies, IL-6 biomarker data, conference presentations, manufacturing readiness for Symphony cartridges, antibody production for test components, and regulatory preparation. Company updates also include financing activity, warrant exercises, reverse stock splits, and other capitalization matters. The Symphony System does not yet have U.S. FDA regulatory clearance and requires authorization before it can be marketed as a diagnostic product in the United States.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced a successful $21.6 million IPO and progress on its IL-6 test for sepsis triage. The company initiated clinical testing in October 2021, with a planned FDA Pre-Submission filing in January 2022. Following positive steps, Bluejay aims to expand testing and file a 510(k) marketing application by Q3 2022. Financial results show a net loss of $1.19 million for Q3 2021, up from $128,000 in Q3 2020, with R&D expenses significantly increasing due to clinical trial preparations. Cash and equivalents rose to $2.33 million by September 30, 2021.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the pricing of its Initial Public Offering (IPO) of 2,160,000 units at $10.00 each, generating gross proceeds of approximately $21.6 million. Each unit comprises one share of common stock, one Class A warrant, and one Class B warrant, with specific exercise prices and conditions. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. The shares will trade under the ticker BJDX starting November 10, 2021. The funds will support the development of the IL-6 Sepsis triage product and general corporate purposes.